| | Stage | Outcome | Total (%) | | None | Recurrence (%) | Recurrent sites (N) |
| | IA | 8 | 1 (11.1) | Vulva (1) | 9 (7.0) | | IB | 25 | 5 (17.2) | Groin node (3), vulva (2) | 30 (23.5) | | II | 23 | 10 (31.3) | Groin node (4), vulva (6) | 33 (25.9) | | IIIA | 12 | 7 (36.8) | Groin node (3), vulva(1), vulva and groin node (1), groin node and skin (1), lung and supraclavicular node (1) | 19 (14.9) | | IIIB | 5 | 2 (28.6) | Groin node (1), vulva (1) | 7 (5.4) | | IIIC | 5 | 8 (61.5) | Groin node (4), vulva (3), vulva and groin node (1) | 13 (10.2) | | IVA | 3 | 6 (66.7) | Groin node (4), vulva (2) | 9 (7.0) | | IVB | 2 | 6 (75.0) | Lung (1), liver (1), breast (1), vulva (1), groin node and skin (2) | 8 (6.1) | | Total | 82 | 45 (35.4) | Vulva (17), groin node (19), vulva and groin node (2), groin node and skin (3), lung and supraclavicular node (1), lung (1), liver (1), breast (1) | 127 (100) |
|
|
